As someone who focuses on the defense sector, I’m no stranger to massive one-day stock surges.
When Russia invaded Ukraine, my portfolio went bananas.
When Hamas attacked Israel last October, it shot up again.
And more recently, when shipping vessels came under fire from Iranian proxy groups, what do you think happened?
Defense stocks surged.
But here’s the thing…
Even I — someone who’s been on the receiving end of these massive one-day defense stock explosions — can admit that they’re few and far in between.
The simple fact is most defense stocks are already mammoth. So while they may steadily advance thanks to rising defense budgets and get juicy tailwinds whenever chaos breaks out…
Those big-time, one-day shots don’t occur as often as I’d like.
And if we’re being honest, that’s probably for the best.
Join Wealth Daily today for FREE. We’ll keep you on top of all the hottest investment ideas before they hit Wall Street. Become a member today, and get our latest free report: “How to Make Your Fortune in Stocks”The Best Free Investment You’ll Ever Make
It contains full details on why dividends are an amazing tool for growing your wealth.
However, there is one investing sector where big, one-day blasts occur as a matter of routine…
And that’s the biotech sector.
That’s because when it comes to pharmaceuticals, there’s a litany of milestones that each and every product must hit before it goes to market.
There’s an entire gauntlet of trials and tests that needs to be run before a drug can be prescribed safely.
It’s an intense process and not every drug makes it through, but every hurdle that is cleared creates a massive profit tsunami for investors.
And that happens more frequently than you might realize.
In 2022, the FDA approved 37 new drugs, which means the government approved an average of three new treatments each month.
Furthermore, there are nearly 880 publicly traded biotech companies currently developing a grand total of 8,000 new drugs as we speak.
Each one of those 8,000 drugs has to go through all 12 steps of the FDA pipeline.
And each of those 12 steps is a potential catalyst event that can send a biotech stock into the stratosphere.
Do the math on that and it’s 96,000 opportunities for investors to hit those single-day windfalls.
Because each time one of these biotech companies clears one of these steps, it’s a signal to the market — a clear indication that its drug or treatment is moving closer to becoming a money-minting machine.
The next Lipitor or Ozempic.
I’m not kidding you when I tell you these stock gains are wild, either.
Celgene, for example, returned over 6,200% for investors before being taken over by Bristol-Myers Squibb.
Questcor Pharmaceuticals skyrocketed a total of 33,428% as its novel treatments for autoimmune disorders blazed through the FDA pipeline one after another.
It was then taken over by Mallinckrodt. (Buyouts and takeovers are another great catalyst for massive one-day stock gains.)
And genetic sequencing superstar Illumina (NASDAQ: ILMN) has generated an eye-popping 47,618% in gains for investors throughout its history.
Now, maybe you missed out on these gains and feel like you missed the boat…
But if that’s the case, fear not…
Because more opportunities like these are coming down the pike.
Like I said, they hit every single month, as a matter of fact.
And all you need to do to get in on the massive stock gains being generated is follow these drugs through the pipeline.
One of the most successful investors I know has even built a calendar around these occurrences.
Better still, he’s in touch with a vast network of more than 250 scientists and doctors.
Check that out here and you’ll be cashing in in no time.
Fight on, Jason Simpkins Simpkins is the founder and editor of Secret Stock Files, an investment service that focuses on companies with assets — tangible resources and products that can hold and appreciate in value. He covers mining companies, energy companies, defense contractors, dividend payers, commodities, staples, legacies and more… In 2023 he joined The Wealth Advisory team as a defense market analyst where he reviews and recommends new military and government opportunities that come across his radar, especially those that spin-off healthy, growing income streams. For more on Jason, check out his editor’s page. Be sure to visit our Angel Investment Research channel on YouTube and tune into Jason’s podcasts. Want to hear more from Jason? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on. 
